Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
纳斯达克股票代码:QNRX-GET评级周三午盘下跌2.4%。该股一度跌至4.45美元,最后报4.98美元。午盘成交量为7,351,853股,较646,993股的平均成交量增加1,036%。该股此前收盘价为5.10美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
几家券商最近发布了关于QNRX的报告。拉登堡THALM/SH SH在5月6日星期五的一份研究报告中开始报道Quoin PharmPharmticals。他们对该公司的评级为“买入”,目标价为25美元。Maxim Group在5月26日星期四的一份研究报告中将Quoin PharmPharmticals的目标价下调至25.00美元。
Quoin Pharmaceuticals Stock Performance
Quoin制药类股表现
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
该公司的50日简单移动均线切入位在6.04美元,200日简单移动均线切入位在11.38美元。
Institutional Investors Weigh In On Quoin Pharmaceuticals
机构投资者看好Quoin制药公司
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
一家机构投资者最近买入了Quoin PharmPharmticals股票的新头寸。根据Virtu Financial LLC最近提交给美国证券交易委员会的13F文件,该公司在第一季度购买了Quoin PharmPharmticals,Ltd.(纳斯达克代码:QNRX-GET Rating)的新股票头寸。该机构投资者购买了42,665股该公司股票,价值约57,000美元。在最近的报告期结束时,Virtu Financial LLC拥有Quoin制药公司约0.51%的股份。机构投资者持有该公司21.72%的股份。
Quoin Pharmaceuticals Company Profile
Quoin制药公司简介
(Get Rating)
(获取评级)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Quoin PharmPharmticals,Ltd.是一家专业制药公司,专注于开发治疗罕见和孤儿疾病的产品。该公司的主导产品是QRX003,一种治疗Netherton综合征的外用洗剂。它还开发了用于治疗营养不良性大疱性表皮松解症的QRX004;以及治疗罕见皮肤病的QRX006。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免费获取StockNews.com关于Quoin PharmPharmticals的研究报告(QNRX)
- 大型和小型石油和天然气类股盈利后反弹
- 连续十年上涨的两只道指股票
- Rite Aid会再次成为收购目标吗?
- 投资石油股票的方式和原因
- 投资黄金股票的方式和原因
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Quoin PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Quoin制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。